Question 1

What is Delix Therapeutics?

Accepted Answer

Delix Therapeutics is a Entity.

Question 2

How often does Delix Therapeutics appear in global news?

Accepted Answer

Tracked across 1 news events drawn from 6 articles.

Question 3

When was Delix Therapeutics first tracked by Ergen?

Accepted Answer

First tracked on May 28, 2026.

Question 4

When was Delix Therapeutics last mentioned in news?

Accepted Answer

Last active on May 28, 2026.

Question 5

What is Delix Therapeutics's current news sentiment?

Accepted Answer

Aggregate sentiment score: 70 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Question 6

How prominent is Delix Therapeutics in global news coverage?

Accepted Answer

Attention score of 4, derived from article volume and coverage intensity across 1 events.

Question 7

What is the most recent event involving Delix Therapeutics?

Accepted Answer

Delix Zalsupindole Phase 1b Results (May 28, 2026, 6 articles).

Question 8

How did the "Delix Zalsupindole Phase 1b Results" event impact Delix Therapeutics?

Accepted Answer

Delix Therapeutics presented positive Phase 1b data for its novel neuroplastogen zalsupindole (DLX-001) for Major Depressive Disorder, supporting at-home administration in future trials. This advancement could significantly impact the company's drug development pipeline and market position.

Question 9

How is this data collected?

Accepted Answer

Ergen aggregates thousands of global news sources and extracts structured events, entities, and relationships with sentiment and attention metrics. Pages are daily static snapshots from the platform's live database.